Madrigal Pharmaceuticals, Inc. financial data

Symbol
MDGL on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Former names
SYNTA PHARMACEUTICALS CORP (to 8/1/2016)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 520 % +94.1%
Debt-to-equity 63.8 % -55.2%
Return On Equity -129 % +54.9%
Return On Assets -78.5 % +33.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.3M shares +16.5%
Common Stock, Shares, Outstanding 19.9M shares +8.71%
Entity Public Float 3.16B USD +221%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 20M shares +9.97%
Weighted Average Number of Shares Outstanding, Diluted 20M shares +9.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 108M USD +125%
Operating Income (Loss) -454M USD -44.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -444M USD -41.2%
Earnings Per Share, Basic -23.1 USD/shares -27.6%
Earnings Per Share, Diluted -23.1 USD/shares -27.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 623M USD +449%
Cash, Cash Equivalents, and Short-term Investments 1.06B USD
Inventory, Net 854K USD
Assets, Current 1.07B USD +224%
Property, Plant and Equipment, Net 1.74M USD +240%
Operating Lease, Right-of-Use Asset 1.59M USD +143%
Assets 1.08B USD +226%
Accounts Payable, Current 21.5M USD +77.5%
Employee-related Liabilities, Current 17M USD
Accrued Liabilities, Current 92.3M USD +7.84%
Liabilities, Current 114M USD +16.3%
Operating Lease, Liability, Noncurrent 1.05M USD
Liabilities 232M USD +27%
Accumulated Other Comprehensive Income (Loss), Net of Tax -172K USD -100%
Retained Earnings (Accumulated Deficit) -1.48B USD -42.7%
Stockholders' Equity Attributable to Parent 851M USD +467%
Liabilities and Equity 1.08B USD +226%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -149M USD -77.4%
Net Cash Provided by (Used in) Financing Activities 574M USD +989%
Net Cash Provided by (Used in) Investing Activities 98.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 19.9M shares +8.71%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 523M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 623M USD +449%
Deferred Tax Assets, Valuation Allowance 383M USD +41.3%
Deferred Tax Assets, Gross 383M USD +41.4%
Operating Lease, Liability 1.71M USD +185%
Payments to Acquire Property, Plant, and Equipment 357K USD +920%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -444M USD -41.3%
Lessee, Operating Lease, Liability, to be Paid 1.86M USD +199%
Operating Lease, Liability, Current 542K USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Two 478K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 937K USD +50.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +59.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 148K USD +640%
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Deferred Tax Assets, Operating Loss Carryforwards 122M USD +78%
Preferred Stock, Shares Issued 2.37M shares 0%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.1M USD +57.1%
Preferred Stock, Shares Outstanding 2.37M shares 0%
Depreciation, Depletion and Amortization 168K USD +35.5%
Deferred Tax Assets, Net of Valuation Allowance 117K USD
Share-based Payment Arrangement, Expense 58.4M USD +64.9%
Interest Expense 14.2M USD +126%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%